ESSA is developing an investigational treatment for prostate cancer, EPI-7386, which blocks the N-terminal domain, located on the opposite end of the androgen receptor from the ligand-binding domain. Through this novel mechanism of action, ESSA is focused on providing a potential meaningful clinical benefit to patients with prostate cancer at all stages of the disease.